Citius Oncology Files 8-K Report
Ticker: CTOR · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1851484
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Citius Oncology filed an 8-K on 6/17/25 covering other events and financials.
AI Summary
On June 17, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as TenX Keane Acquisition until March 15, 2021, is incorporated in Delaware and has its principal executive offices in Cranford, NJ.
Why It Matters
This 8-K filing indicates routine corporate reporting, including financial statements and exhibits, which provides transparency to investors about the company's current status and activities.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate disclosure rather than a significant event.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- TenX Keane Acquisition (company) — Former company name
- June 17, 2025 (date) — Date of report
- 001-41534 (other) — SEC File Number
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Citius Oncology, Inc.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate disclosures.
When was Citius Oncology, Inc. formerly known by another name?
The company was formerly known as TenX Keane Acquisition until March 15, 2021.
What is the principal executive office address for Citius Oncology, Inc.?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the SEC file number for Citius Oncology, Inc.?
The SEC file number is 001-41534.
On what date was this 8-K report filed?
The report was filed on June 17, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding CITIUS ONCOLOGY, INC. (CTOR).